2 weeks Ago
X4 Pharmaceuticals, Inc. ( NASDAQ: XFOR ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Christophe Arbet-Engels - Chief Medical Officer Mark Baldry - CCO Conference Call Participants Kristen Kluska - Cantor Edward Tenthoff - Piper Sandler Swayampakula Ramakanth - H.C.
Wainwright Stephen Willey - Stifel David Bautz - Zacks Operator Greetings, and welcome to the X4 Pharmaceuticals Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.
As a reminder, this conference call is being recorded. It is now my pleasure to introduce your host, Dan Ferry from LifeSci Advisors. Please begin.
Daniel Ferry Thank you, operator, and good morning, everyone. Thank you for joining us today for the special earnings call during which X4 will focus on providing a business update and, importantly, data and results from its now completed Phase II study of mavorixafor in chronic neutropenia. As a reminder, on today's call, the company will be making forward-looking statements regarding regulatory and product development and commercialization plans, as well as research activities and financial projections.
These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Description of these risks can be found in X4's most recent filings with the SEC, including this year's Form 10-K, which was filed on March 21, 2024, and in the company's Form 10-Q for the third quarter, which is expected to be filed shortly. Presenting on today's call will be Dr.
Paula Ragan, X4's President and CEO; and the company's Chief Medical Officer, Dr. Christophe Arbet-Engels. I'll now turn it over to Paula Ragan to run through today's agenda.
Paula? Paula Ragan Thank you, Dan, and thank you all for joining us. Today, we.
